The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer

BJU International

Volumn 107, Issue 3, 2011, Pages 404-408

  Otto, Wolfgang ^a   Denzinger, Stefan ^a   Fritsche, Hans Martin ^a   Burger, Maximilian ^a   Wieland, Wolf F ^a   Hofstädter, Ferdinand ^a   Hartmann, Arndt ^b   Bertz, Simone ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

1973 WHO classification; 2004 WHO classification; grading; inter observer variety; pT1 bladder cancer

Indexed keywords

BCG VACCINE;

ADJUVANT THERAPY; AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

CYSTECTOMY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; PROGNOSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM; WORLD HEALTH ORGANIZATION;

EID: 79251546459     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09515.x     Document Type: Article

References (33)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92
2. Mhawech-Fauceglia P, Fischer G, Alvarez V, Ahmed A, Herrmann FR,. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: A high throughput tissue microarray analysis. BJU Int 2007; 100: 1182-7
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
4. Sobin LH, Wittekind C,. TNM Classification of Malignant Tumours, 6 edn. New York: Wiley-Liss, 2002
5. Mhawech P, Iselin C, Pelte MF,. Value of Immunohistochemistry in Staging T1 Urothelial Bladder Carcinoma. Eur Urol 2002; 42: 459-63
6. Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003; 14: 1419-24
7. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005; 48: 231-38
8. Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006; 59: 83-8
9. Masood S, Sriprasad S, Palmer JH, Mufti GR,. T1G3 bladder cancer-Indications for early cystectomy. Int Urol Nephrol 2004; 36: 41-4
10. Bryan RT, Wallace DMA,. 'Superficial' bladder cancer-time to uncouple pT1 tumours from pTa tumours. BJU Int 2002; 90: 846-52
11. van der Meijden A, Boehle A, Lobel B, et al. Guidelines on TaT1 (Non-muscle invasive) Bladder cancer. Eur Assoc Urol 2007
12. Zhang YS, Li HZ, Zhang RQ, Shi BB,. Characteristics of recurrence of T1G3 transitional cell carcinoma of the bladder. Zhonghua Yi Xue Za Zhi 2006; 86: 1305-8
13. Fritsche HM, Burger M, Svatek RS, et al. Characteristics and outcomes of patients with clinical t1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 2010; 57: 300-9
14. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE,. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100
15. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-5; discussion 475-7
16. Hurle R, Losa A, Manzetti A, Lembo A,. Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: A 7-year follow-up. Urology 1999; 54: 258-63
17. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H,. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumours: recurrence, progression and success. Eur Urol 1998; 34: 67-72
18. Brake M, Loertzer H, Horsch R, Keller H,. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697-705
19. Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN,. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227-31
20. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M,. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2007; 53: 146-52
21. Bergkvist A, Ljungqvist A, Moberger G,. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965; 130: 371-78
22. Mostofi FK, Sobin LH, Tosoni I,. Histological Typing of Urinary Bladder Tumours. International Histological Classification of Tumours, No 19. Geneva: World Health Organisation, 1973
23. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000; 85: 48-53
24. Bol MGW, Baak JPA, Buhr-Wildhagen S, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003; 169: 1291-94
25. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2009 [Epub ahead of print]
26. Mikulowski P, Hellsten S,. T1 G1 urinary bladder carcinoma: Fact or fiction? Scand J Urol Nephrol 2005; 39: 135-37
27. Epstein I, Amin MB, Reuter VR, Mostofi FK,. The World Health Organisation/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-48
28. Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study. Eur Urol 2008; 54: 835-44
29. Burger M, Denzinger S, Wieland WF, Stief CG, Hartmann A, Zaak D,. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset? BJU Int 2008; 102: 194-7
30. Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG,. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 2003; 56: 91-5
31. MacLennan GT, Kirkali Z, Cheng L,. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007; 51: 889-98
32. Van der Kwast TH, Zlotta AR, Fleshner N, Jewett M, Lopez-Beltran A, Montironi R,. Thirty-five years of noninvasive bladder carcinoma: A plea for the use of papillary intraurothelial neoplasia as new terminology. Anal Quant Cytol Histol 2008; 30: 309-15
33. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25